Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CSX Corporation (CSX) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
CSX CorporationTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs CSX Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while CSX Corporation trades at $50.03 (market cap $92.88B). The key difference: CSX Corporation is far larger — about 18.4× ACADIA Pharmaceuticals Inc.'s market cap, and CSX Corporation pays a 1.12% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADCSX
Market Cap
$5.06B$92.88B
Sector
HealthIndustrials
52-Week High
$29.41$53.21
52-Week Low
$20.06$32.05
Enterprise Value
$4.18B$110.85B
Dividend Yield
1.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.

The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.

CSX Corporation

CSX trades at $50.27, down 0.85% on the day, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and 17% operating income increase. The company raised 2026 guidance to mid-to-high-single-digit revenue growth and margin expansion. Analyst consensus is bullish with 59% buy ratings and a $52.57 price target, implying 4.6% upside from current levels.

Outlook remains positive due to strong volume growth and operational efficiency, but risks include fuel cost pressures and economic sensitivity. The stock offers value through consistent dividends and earnings momentum, though valuation multiples appear elevated with P/E at 29.23. Investors should monitor execution against raised guidance and industry headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About CSX Corporation

Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.

Read more on CSX